A majority of participants in the US survey agreed they have a responsibility to bring awareness of the health effects of climate change to patients and policymakers.
The chart review summarized the results in 11 pediatric patients, ages 8 to 18 years, all with a diagnosis of alopecia areata, who were treated with tofacitinib.
The guidelines are the first in a four-part series on AD expected to be published over the next 1-2 years. Subsequent guidelines will address topicals, phototherapy/systemics, and pediatrics.